NASDAQ:PCVX Vaxcyte (PCVX) Stock Forecast, Price & News $50.84 -1.61 (-3.07%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$50.78▼$52.7050-Day Range$46.00▼$53.1052-Week Range$20.49▼$54.97Volume1.00 million shsAverage Volume545,042 shsMarket Capitalization$4.77 billionP/E RatioN/ADividend YieldN/APrice Target$65.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Vaxcyte MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside27.9% Upside$65.00 Price TargetShort InterestBearish8.04% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 3 Articles This WeekInsider TradingSelling Shares$158,460 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.07) to ($3.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.72 out of 5 starsMedical Sector924th out of 962 stocksBiological Products, Except Diagnostic Industry156th out of 159 stocks 3.5 Analyst's Opinion Consensus RatingVaxcyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $65.00, Vaxcyte has a forecasted upside of 27.9% from its current price of $50.84.Amount of Analyst CoverageVaxcyte has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.04% of the outstanding shares of Vaxcyte have been sold short.Short Interest Ratio / Days to CoverVaxcyte has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.Change versus previous monthShort interest in Vaxcyte has recently decreased by 2.58%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVaxcyte does not currently pay a dividend.Dividend GrowthVaxcyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PCVX. Previous Next 3.1 News and Social Media Coverage News SentimentVaxcyte has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Vaxcyte this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Vaxcyte to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaxcyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $158,460.00 in company stock.Percentage Held by InsidersOnly 3.60% of the stock of Vaxcyte is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Vaxcyte are expected to decrease in the coming year, from ($3.07) to ($3.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxcyte is -15.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxcyte is -15.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxcyte has a P/B Ratio of 4.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vaxcyte (NASDAQ:PCVX) StockVaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Read More PCVX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PCVX Stock News HeadlinesSeptember 24, 2023 | americanbankingnews.comVaxcyte (NASDAQ:PCVX) Stock Price Down 2.4%September 19, 2023 | finance.yahoo.comVaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare ConferenceSeptember 26, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. August 22, 2023 | msn.comCantor Fitzgerald Reiterates Vaxcyte (PCVX) Overweight RecommendationAugust 17, 2023 | msn.comStrong Financials And Pipeline Position Vaxcyte For SuccessAugust 9, 2023 | msn.comNeedham Reiterates Vaxcyte (PCVX) Buy RecommendationAugust 9, 2023 | finanznachrichten.deVaxcyte, Inc.: Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business UpdateJuly 11, 2023 | finance.yahoo.comVaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in InfantsSeptember 26, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. May 29, 2023 | finance.yahoo.comWall Street Analysts Think Vaxcyte, Inc. (PCVX) Could Surge 33.33%: Read This Before Placing a BetMay 17, 2023 | seekingalpha.comVaxcyte: Positive Phase 2 Results Elevate Confidence In VAX-24's PotentialMay 15, 2023 | markets.businessinsider.comBTIG Sticks to Their Buy Rating for Vaxcyte (PCVX)May 12, 2023 | finance.yahoo.comWall Street Analysts Believe Vaxcyte, Inc. (PCVX) Could Rally 26.15%: Here's is How to TradeMay 10, 2023 | morningstar.comVaxcyte Inc Ordinary SharesMay 10, 2023 | finance.yahoo.comVaxcyte Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 3, 2023 | finance.yahoo.comVaxcyte to Present at the BofA Securities 2023 Health Care ConferenceApril 21, 2023 | finance.yahoo.comVaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesApril 19, 2023 | finance.yahoo.comBiotech Stock Roundup: MDGL, PCVX Up on Study Data, MRNA Provides UpdatesApril 19, 2023 | finanznachrichten.deVaxcyte, Inc.: Vaxcyte Announces Pricing of $500 Million Public OfferingApril 19, 2023 | msn.comTD Cowen Initiates Coverage of Vaxcyte (PCVX) with Outperform RecommendationApril 19, 2023 | finance.yahoo.comVaxcyte Announces Pricing of $500 Million Public OfferingApril 18, 2023 | benzinga.comVaxcyte Stock (NASDAQ:PCVX), DividendsApril 17, 2023 | msn.comNew Vaccine Data Sends Vaxcyte Stock Blasting UpApril 17, 2023 | bizjournals.comPneumonia vaccine trial data sends Peninsula biotech stock higherApril 17, 2023 | msn.comWhy Vaxcyte Stock Is Sliding After HoursApril 17, 2023 | msn.comVaxcyte spikes after mid-stage data for pneumococcal vaccineApril 16, 2023 | finance.yahoo.comVaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 StudiesSee More Headlines Receive PCVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter. Email Address PCVX Company Calendar Last Earnings8/08/2023Today9/26/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PCVX CUSIPN/A CIK1649094 Webwww.vaxcyte.com Phone650-837-0111FaxN/AEmployees158Year FoundedN/APrice Target and Rating Average Stock Price Forecast$65.00 High Stock Price Forecast$70.00 Low Stock Price Forecast$58.00 Forecasted Upside/Downside+27.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-223,490,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-26.20% Return on Assets-24.61% Debt Debt-to-Equity RatioN/A Current Ratio21.76 Quick Ratio21.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.00 per share Price / Book4.24Miscellaneous Outstanding Shares93,847,000Free Float90,469,000Market Cap$4.77 billion OptionableNot Optionable Beta0.88 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Grant E. Pickering M.B.A. (Age 55)Co-Founder, CEO & Director Comp: $1.1MMr. Andrew L. Guggenhime M.B.A. (Age 55)Pres & CFO Comp: $839.65kMr. James Wassil M.B.A. (Age 54)M.S., Exec. VP & COO Comp: $826.3kMr. Mikhail Eydelman J.D. (Age 42)Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. Comp: $793.22kMr. Paul W. Sauer M.B.A. (Age 62)MBA, Sr. VP of Process Devel. & Manufacturing Comp: $608.96kDr. Ashish Khanna M.B.A. (Age 51)Ph.D., Co-Founder Dr. Jeff Fairman Ph.D. (Age 59)Co-Founder & VP of Research Ms. Elvia Cowan (Age 50)Sr. VP of Fin. & Principal Accounting Officer Ms. Janet GraesserVP of Corp. Communications & Investor RelationsKaren AldereteExec. Director of HRMore ExecutivesKey CompetitorsAbcamNASDAQ:ABCMHalozyme TherapeuticsNASDAQ:HALOGinkgo BioworksNYSE:DNACRISPR TherapeuticsNASDAQ:CRSPKrystal BiotechNASDAQ:KRYSView All CompetitorsInsiders & InstitutionsJim WassilSold 3,000 sharesTotal: $158,460.00 ($52.82/share)Perceptive Advisors LLCBought 444,122 shares on 8/24/2023Ownership: 1.720%California State Teachers Retirement SystemBought 15,542 shares on 8/21/2023Ownership: 0.097%Teachers Retirement System of The State of KentuckyBought 2,525 shares on 8/21/2023Ownership: 0.023%Affinity Asset Advisors LLCSold 48,300 shares on 8/21/2023Ownership: 0.015%View All Insider TransactionsView All Institutional Transactions PCVX Stock - Frequently Asked Questions Should I buy or sell Vaxcyte stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxcyte in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PCVX shares. View PCVX analyst ratings or view top-rated stocks. What is Vaxcyte's stock price forecast for 2023? 6 brokerages have issued 1 year target prices for Vaxcyte's shares. Their PCVX share price forecasts range from $58.00 to $70.00. On average, they anticipate the company's stock price to reach $65.00 in the next year. This suggests a possible upside of 27.9% from the stock's current price. View analysts price targets for PCVX or view top-rated stocks among Wall Street analysts. How have PCVX shares performed in 2023? Vaxcyte's stock was trading at $47.95 at the beginning of the year. Since then, PCVX shares have increased by 6.0% and is now trading at $50.84. View the best growth stocks for 2023 here. When is Vaxcyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our PCVX earnings forecast. How were Vaxcyte's earnings last quarter? Vaxcyte, Inc. (NASDAQ:PCVX) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.04. What ETFs hold Vaxcyte's stock? ETFs with the largest weight of Vaxcyte (NASDAQ:PCVX) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Alger 35 ETF (ATFV), Alger Mid Cap 40 ETF (FRTY), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC) and Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Vaxcyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxcyte investors own include NVIDIA (NVDA), Twilio (TWLO), Boeing (BA), Overstock.com (OSTK), Pure Storage (PSTG), QUALCOMM (QCOM), Riot Platforms (RIOT), American Tower (AMT), Avid Technology (AVID) and CalAmp (CAMP). When did Vaxcyte IPO? (PCVX) raised $210 million in an IPO on Friday, June 12th 2020. The company issued 14,000,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO and Cantor and Needham & Company were co-managers. What is Vaxcyte's stock symbol? Vaxcyte trades on the NASDAQ under the ticker symbol "PCVX." Who are Vaxcyte's major shareholders? Vaxcyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (8.41%), BlackRock Inc. (7.53%), Capital Research Global Investors (3.58%), State Street Corp (3.37%), Alliancebernstein L.P. (2.01%) and Braidwell LP (1.84%). Insiders that own company stock include Andrew Guggenhime, Grant Pickering, Group Holdings (Sbs) Advis Tpg, Heath Lukatch, Jane Wright-Mitchell, Jeff Fairman, Jim Wassil, Paul Sauer, Ra Capital Healthcare Fund Lp, Ra Capital Management, LP and Robert Lorne Hopfner. View institutional ownership trends. How do I buy shares of Vaxcyte? Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vaxcyte's stock price today? One share of PCVX stock can currently be purchased for approximately $50.84. How much money does Vaxcyte make? Vaxcyte (NASDAQ:PCVX) has a market capitalization of $4.77 billion. The company earns $-223,490,000.00 in net income (profit) each year or ($3.36) on an earnings per share basis. How many employees does Vaxcyte have? The company employs 158 workers across the globe. How can I contact Vaxcyte? Vaxcyte's mailing address is 353 HATCH DRIVE, FOSTER CITY CA, 94404. The official website for the company is www.vaxcyte.com. The company can be reached via phone at 650-837-0111 or via email at investors@vaxcyte.com. This page (NASDAQ:PCVX) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.